PLUS THERAPEUTICS PSTV 深 沪
等待开盘 07-01 09:30:00 美东时间
4.37
+0.080
+1.86%
华盛通- 最 高4.43
- 今 开4.31
- 成交量 16.39万股
- 最 低 4.20
- 昨 收 4.29
- 总市值 3008.26万
- 52周最高 23.425
- 市盈率 静 --
- 换手率 2.38%
- 52周最低 2.90
- 委 比 99.30%
- 总股本 688.39万
- 历史最高 8583.75
- 量 比 0.45
- 振 幅 5.36%
- 历史最低 3.225
- 每 手 1
- 风险率 4.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Plus Therapeutics wins Elevance Health coverage deal
Plus Therapeutics (PSTV) shares rose in early premarket trading after its subsidiary CNSide Diagnostics announced an agreement with Elevance Health (ELV) to expand coverage for a cancer screening test...
06-25 20:02
CNSide Diagnostics Strikes Deal With Elevance Health To Offer CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay, Effective May 1, 2026
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed a national agreement with Elevance Health, Inc. (NYSE:ELV), effective May 1, 2026, covering approximately 45.4 million people throughout the Unit...
06-25 19:35
Plus Therapeutics to Provide Business Update Call on June 30, 2026
Plus Therapeutics will host a business update conference call on June 30, 2026, at 8:30 a.m. ET, discussing progress on its CNS cancer diagnostics, lead drug Reyobiq, and integrated AI plans. CEO Marc H. Hedrick highlights advancements in diagnostics, therapeutics, and AI, aiming to improve outcomes for CNS oncology patients and deliver long-term value to shareholders. The call will also cover the CNSide diagnostic launch and the company's vision...
06-23 11:30
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analyst ratings page.
06-08 21:52
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex June 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Allstate and Teleflex on Monday. HIGHLIGHTS * Adobe Inc ADBE.O : TD Cowen cuts target price to $285 from $310
06-08 16:01
Plus Therapeutics Launches New At-The-Market Equity Program
An announcement from Plus Therapeutics ( ($PSTV) ) is now available. On June 1,...
06-06 06:26
Plus Therapeutics Subsidiary's Clinical Laboratory Gets Accreditation From College Of American Pathologists
CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous
06-04 19:32
Plus Therapeutics Presents New Data On Health Economics Trial Evaluating Economic Impact Of Earlier Detection And Therapeutic Management Of LM Through CNSide Cerebrospinal Fluid Assay
Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today
05-26 19:35
Plus Therapeutics Partners With Ephemeral Technologies To Deliver Unique AI Execution Platform For CNS Oncology
Partnership to deliver a novel AI-native integrated CNS oncology platformPlatform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision
05-19 19:34
